Search
Subscribe Now
Home
Latest
News
North America
Europe
Asia
Middle East
Global
Coins2Day 500
Coins2Day 500 U.S.
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Great Place To Work
Analytics
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Home
Latest
Latest
News
North America
Europe
Asia
Middle East
Global
Coins2Day 500
Coins2Day 500
Coins2Day 500 U.S.
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Finance
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Rankings
Great Place To Work
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
home
home
Gilead Sciences
Gilead Sciences
Digital Assets Editor
By
Coins2Day Editors
October 30, 2025
Digital Assets Editor
By
Coins2Day Editors
August 7, 2025
Health
U.S. approves twice-a-year shot to prevent HIV but cuts to public health and foreign aid cloud its prospects
By
Lauran Neergaard
and
The Associated Press
June 19, 2025
Digital Assets Editor
By
Coins2Day Editors
April 24, 2025
Digital Assets Editor
By
Coins2Day Editors
February 11, 2025
Health
In patient with long-term COVID-19, coronavirus mutated to resist antiviral Remdesivir
By
Jason Gale
and
Bloomberg
November 11, 2021
Conferences
Can the pandemic-induced collaboration among health care companies have a real impact on inequality?
By
Sheryl Estrada
April 29, 2021
Conferences
Gilead’s remdesivir is now used to treat half of hospitalized COVID patients
By
Sy Mukherjee
April 28, 2021
Health
Gilead shares jump on FDA approval of remdesivir
By
Robert Langreth
and
Bloomberg
October 23, 2020
Health
Gilead says remdesivir slashes coronavirus deaths. But it’s complicated
By
Sy Mukherjee
July 10, 2020
Health
Gilead to charge thousands for coronavirus treatment drug that critics say should cost $1
By
Robert Langreth
and
Bloomberg
June 29, 2020
Newsletters
The April stocks rally defied the odds. Here’s what’s driving markets
By
Bernhard Warner
April 30, 2020
Magazine
Big Pharma has the chance to come to the world’s rescue
By
Sy Mukherjee
April 20, 2020
Health
Gilead stock surges on report of coronavirus drug patients ‘seeing rapid recoveries’
By
Drew Armstrong
and
Bloomberg
April 16, 2020
Newsletters
Gilead made a remarkable request of the FDA in regard to its coronavirus drug
By
Sy Mukherjee
March 25, 2020
Most Popular
Europe
Denmark offered to trade Greenland to the U.S. in 1910—and America thought it was crazy
By
Steven Lamy
and
The Conversation
Personal Finance
Sweden abolished its wealth tax 20 years ago. Then it became a 'paradise for the super-rich'
By
Miranda Sheild Johansson
and
The Conversation
North America
Gates Foundation plans to give away $9 billion in 2026 to prepare for the 2045 closure while slashing hundreds of jobs
By
Sydney Lake